Protection against hepatitis B by the Butang® recombinant vaccine in newborn children in South Brazil
Mem. Inst. Oswaldo Cruz
; 101(5): 551-553, Aug. 2006. graf
Article
in En
| LILACS
| ID: lil-437041
Responsible library:
BR1.1
ABSTRACT
The prevention of hepatitis B by vaccination is one of the most efficient tools to avoid the transmission of the virus. This study evaluated the immunogenicity of the national vaccine Butang® in children born in Campo Mourão City, state of Paraná, Brazil, aged 7 to 12 months, by determining the anti-HBsAg antibodies levels after completion of the National Immunization Program Protocol for hepatitis B. All 70 children evaluated by the MEIA method (immune-enzymatic micro particles) showed seroconversion to the Butang® vaccine. Nine children (12.9 percent) presented a low response, with anti-HBs titers between 11 and 100 mUI/ml; 39 children (55.7 percent) showed a good response to the vaccine, with titers between 101 and 1000 mUI/ml; and 22 children (31.4 percent) showed antibodies titers higher than 1000 mUI/ml. The mean titer of the anti-HBs antibody titers was 1408.1 ± 2870.26 mUI/ml (15.7 to 19560.0 mUI/ml). The levels of antibodies produced by the prematurely-born children were not statistically different from those found in the newborns. Fifty-five children were also evaluated through the ELFA method (ELISA with a final detection in fluorescence), which presented similar results. The results obtained in our study corroborated the effectiveness of the national vaccine Butang® in newborn children of Campo Mourão City, Paraná, even if they were premature.
Full text:
1
Index:
LILACS
Main subject:
Recombinant Proteins
/
Enzyme-Linked Immunosorbent Assay
/
Hepatitis B Vaccines
/
Hepatitis B
/
Hepatitis B Antibodies
Limits:
Female
/
Humans
/
Infant
/
Male
/
Newborn
Country/Region as subject:
America do sul
/
Brasil
Language:
En
Journal:
Mem. Inst. Oswaldo Cruz
Journal subject:
MEDICINA TROPICAL
/
PARASITOLOGIA
Year:
2006
Type:
Article